MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

FDA Approves First-of-Kind Kidney Disease Test in 62 Days

FDA Approves First-of-Kind Kidney Disease Test in 62 Days
It's the first test that can help determine if membranous glomerulonephritis is due to the body’s rejection of its own kidney tissue or another cause, like an infection.  

FDA has approved in 62 days a EuroImmun de novo petition to allow marketing of its Anti-PLA2R IFA blood test, the first test that can help determine if a specific type of kidney disease is due to the body’s rejection of its own kidney tissue or another cause, like an infection.

Membranous glomerulonephritis (MGN) is a chronic kidney disease that causes damage to the cluster of blood vessels in the kidney that filter blood and begin the process to remove waste and excess fluid from the blood.

Approval was based on FDA’s review of a clinical study involving 560 blood samples, of which 275 samples were obtained from patients with presumed primary MGN (pMGN), according to an FDA news release. “The test was able to detect pMGN in 77% of the presumed pMGN samples, and gave a false positive result in less than 1% of the other disease samples,” it says.

—Jim Dickinson is MD+DI's contributing editor.

[image courtesy of DIGITALART/FREEDIGITALPHOTOS.NET] 

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish